DCF Advisers LLC Boosts Stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

DCF Advisers LLC boosted its position in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 87.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 539,989 shares of the company's stock after buying an additional 251,511 shares during the quarter. Lifecore Biomedical makes up approximately 1.9% of DCF Advisers LLC's portfolio, making the stock its 17th biggest position. DCF Advisers LLC owned about 1.46% of Lifecore Biomedical worth $4,012,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of LFCR. Geode Capital Management LLC lifted its holdings in shares of Lifecore Biomedical by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company's stock worth $2,948,000 after acquiring an additional 55,703 shares during the last quarter. State Street Corp lifted its stake in Lifecore Biomedical by 10.2% in the third quarter. State Street Corp now owns 334,360 shares of the company's stock worth $1,648,000 after purchasing an additional 30,916 shares during the last quarter. 272 Capital LP boosted its position in Lifecore Biomedical by 511.1% during the third quarter. 272 Capital LP now owns 143,480 shares of the company's stock valued at $707,000 after buying an additional 120,002 shares during the period. Bank of New York Mellon Corp boosted its position in Lifecore Biomedical by 71.9% during the fourth quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company's stock valued at $599,000 after buying an additional 33,690 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Lifecore Biomedical by 23.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 74,427 shares of the company's stock valued at $553,000 after buying an additional 13,922 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Paul Josephs purchased 17,000 shares of the business's stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,717 shares in the company, valued at approximately $3,212,775.58. The trade was a 3.13 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 32.20% of the company's stock.

Lifecore Biomedical Trading Down 1.4 %

Shares of LFCR stock traded down $0.09 during mid-day trading on Tuesday, reaching $6.51. The stock had a trading volume of 238,651 shares, compared to its average volume of 213,209. The firm has a market capitalization of $241.03 million, a PE ratio of -11.63 and a beta of 0.96. The stock's 50-day moving average price is $6.12 and its two-hundred day moving average price is $6.15. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $7.99.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Equities analysts expect that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an "equal weight" rating and set a $6.00 target price on shares of Lifecore Biomedical in a report on Friday, January 3rd.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.